VNRX Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -2201.34% compared to VolitionRX's net margin of -0.77%. VolitionRX's return on equity of -- beat InfuSystems Holdings's return on equity of 5.82%.

VolitionRX has a consensus price target of $2.94, signalling upside risk potential of 355.11%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.00 which suggests that it could grow by 155.48%. Given that VolitionRX has higher upside potential than InfuSystems Holdings, analysts believe VolitionRX is more attractive than InfuSystems Holdings.

VolitionRX has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.31%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $246.4K, which are smaller than InfuSystems Holdings quarterly revenues of $34.7M. VolitionRX's net income of -$5.4M is lower than InfuSystems Holdings's net income of -$267K. Notably, VolitionRX's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 39.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 44.53x versus 0.86x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -2201.34% compared to VolitionRX's net margin of -126.59%. VolitionRX's return on equity of -- beat Retractable Technologies's return on equity of -26.39%.

VolitionRX has a consensus price target of $2.94, signalling upside risk potential of 355.11%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that VolitionRX has higher upside potential than Retractable Technologies, analysts believe VolitionRX is more attractive than Retractable Technologies.

VolitionRX has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

VolitionRX quarterly revenues are $246.4K, which are smaller than Retractable Technologies quarterly revenues of $8.3M. VolitionRX's net income of -$5.4M is higher than Retractable Technologies's net income of -$10.5M. Notably, VolitionRX's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 44.53x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -2201.34% compared to VolitionRX's net margin of -2828.67%. VolitionRX's return on equity of -- beat Catheter Precision's return on equity of -137.84%.

VolitionRX has a consensus price target of $2.94, signalling upside risk potential of 355.11%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 796.86%. Given that Catheter Precision has higher upside potential than VolitionRX, analysts believe Catheter Precision is more attractive than VolitionRX.

VolitionRX has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $246.4K, which are larger than Catheter Precision quarterly revenues of $143K. VolitionRX's net income of -$5.4M is lower than Catheter Precision's net income of -$4M. Notably, VolitionRX's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 44.53x versus 2.56x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -2201.34% compared to VolitionRX's net margin of 0.18%. VolitionRX's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

VolitionRX has a consensus price target of $2.94, signalling upside risk potential of 355.11%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 182.3%. Given that VolitionRX has higher upside potential than Xtant Medical Holdings, analysts believe VolitionRX is more attractive than Xtant Medical Holdings.

VolitionRX has a beta of 1.198, which suggesting that the stock is 19.798% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

VolitionRX has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VolitionRX pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

VolitionRX quarterly revenues are $246.4K, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. VolitionRX's net income of -$5.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, VolitionRX's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VolitionRX is 44.53x versus 0.69x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.